All In Biotech

Drug Trial Radar · NCT04164199

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

404

Actual

Start

Dec 19, 2019

Primary completion

May 23, 2026

Study completion May 23, 2026

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Nov 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).

Conditions

  • Advanced Malignancies

Interventions

  • TislelizumabDrug

    Administered intravenously.

  • PamiparibDrug

    Administered orally.

  • TemozolomideDrug

    Administered orally.

  • SitravatinibDrug

    Administered orally.

  • OciperlimabDrug

    Administered intravenously.

  • BAT1706Drug

    Administered intravenously.

  • FruquintinibDrug

    Administered orally.

  • BGB-15025Drug

    Administered orally.

  • ZanidatamabDrug

    Administered intravenously.

  • BGB-A445Drug

    Administered intravenously.

  • SurzebiclimabDrug

    Administered intravenously.

  • LenvatinibDrug

    Administered orally.

  • LBL-007Drug

    Administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Immune-Mediated Adverse Events, Serious Adverse Events, and Adverse Events Grade 3 or HigherTime frame: up to 7 years

Locations

106 sites in 13 countries. Site status is shown where the registry gives one.

  • Mount Sinai Medical Center Braman Comprehensive Cancer Center

    Miami, Florida

  • Memorial Sloan Kettering Cancer Center Mskcc

    New York, New York

  • Tennessee Oncology, Pllc Nashville

    Nashville, Tennessee

  • Baylor Research Institute

    Dallas, Texas

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Northern Cancer Institute

    St Leonards, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Icon Cancer Centre South Brisbane

    South Brisbane, Queensland, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • The Affiliated Hospital of Military Medical Sciences

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North)

    Guangzhou, Guangdong, China

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Guangdong Provincial Peoples Hospital

    Guangzhou, Guangdong, China

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The Fifth Affiliated Hospital Sun Yat Sen University

    Zhuhai, Guangdong, China

  • The Peoples Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China

  • The Second Affiliated Hospital of Zunyi Medical University

    Zuiyi, Guizhou, China

  • Hainan Cancer Hospital

    Haikou, Hainan, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University Wuhan

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The First Peoples Hospital of Changzhou

    Changzhou, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.